Sandro Vento, PhD

Department Chair

  • 4148 Citations
  • 31 h-Index
1981 …2018
If you made any changes in Pure these will be visible here soon.

Personal profile

External positions

Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 5 Similar Profiles
HIV Infections Medicine & Life Sciences
HIV Medicine & Life Sciences
HIV-1 Medicine & Life Sciences
Highly Active Antiretroviral Therapy Medicine & Life Sciences
Autoimmune Hepatitis Medicine & Life Sciences
Anti-HIV Agents Medicine & Life Sciences
AIDS-Related Opportunistic Infections Medicine & Life Sciences
Chronic Hepatitis Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1981 2018

Acute opisthorchiasis in a Kazakh man

Atygaeva, S., Cainelli, F. & Vento, S., Jun 1 2018, In : Israel Medical Association Journal. 20, 6, p. 395-396 2 p.

Research output: Contribution to journalLetter

Opisthorchiasis

A Rare Case of Nasal NK/T-Cell Lymphoma in a Kazakh Man

Goremykina, M., Gerdt, A., Ibraev, Y., Kalmakbayev, B., Dyakonov, K., Skinder, O. & Vento, S., Dec 1 2018, In : The Israel Medical Association journal : IMAJ. 20, 12, p. 790-791 2 p.

Research output: Contribution to journalLetter

Lethal Midline Granuloma
Kazakhstan
Nose
Lymphoma

Dolutegravir monotherapy: an option for highly adherent HIV1-infected naive patients with relatively low zenith HIV-RNA?

Lanzafame, M., Rizzardo, S., Piacentini, D., Lattuada, E., Chiesi, S. & Vento, S., Jan 1 2018, (Accepted/In press) In : Infectious Diseases.

Research output: Contribution to journalArticle

HIV
RNA
dolutegravir

Dolutegravir monotherapy in HIV-1-suppressed patients: A feasible regimen in real life

Lattuada, E., Lanzafame, M., Nicolè, S., Rigo, F., Cucchetto, G., Concia, E. & Vento, S., Feb 1 2018, In : International Journal of STD and AIDS. 29, 2, p. 206-207 2 p.

Research output: Contribution to journalLetter

HIV-1
dolutegravir

Immunovirological outcome and HIV-1 DNA decay in a small cohort of HIV-1-infected patients deintensificated from Abacavir/Lamivudine/Dolutegravir to Lamivudine plus Dolutegravir

Lanzafame, M., Nicole, S., Rizzardo, S., Piacentini, D., Chiesi, S., Lattuada, E., Diani, E., Carelli, M., Vento, S. & Gibellini, D., Oct 1 2018, In : The new microbiologica. 41, 4, p. 262-267 6 p.

Research output: Contribution to journalArticle

Lamivudine
HIV-1
DNA
Highly Active Antiretroviral Therapy
Therapeutics